These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials. Friedman DJ; Al-Khatib SM; Zeitler EP; Han J; Bardy GH; Poole JE; Bigger JT; Buxton AE; Moss AJ; Lee KL; Steinman R; Dorian P; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Inoue LYT; Sanders GD Am Heart J; 2017 Sep; 191():21-29. PubMed ID: 28888266 [TBL] [Abstract][Full Text] [Related]
4. New York Heart Association functional class and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: Extended follow-up of the DANISH trial. Karacan MN; Doi SN; Yafasova A; Thune JJ; Nielsen JC; Haarbo J; Bruun NE; Gustafsson F; Eiskjær H; Hassager C; Svendsen JH; Høfsten DE; Pehrson S; Køber L; Butt JH Eur J Heart Fail; 2024 Jun; 26(6):1423-1431. PubMed ID: 38733253 [TBL] [Abstract][Full Text] [Related]
5. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability. Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517 [TBL] [Abstract][Full Text] [Related]
6. Outcome of Patients with Advanced Heart Failure Who Receive Device-Based Therapy for Primary Prevention of Sudden Cardiac Death: Insights from the Israeli ICD Registry. Suleiman M; Goldenberg I; Samniah N; Rosso R; Marai I; Pekar A; Khalameizer V; Militianu A; Glikson M Pacing Clin Electrophysiol; 2015 Jun; 38(6):738-45. PubMed ID: 25754272 [TBL] [Abstract][Full Text] [Related]
7. The Benefit of Prophylactic Implantable Cardioverter Defibrillator Implantation in Asymptomatic Heart Failure Patients With a Reduced Ejection Fraction. van der Lingen ACJ; Timmer SAJ; Allaart LJH; Rijnierse MT; van de Ven PM; van Rossum AC; Kemme MJB; van Halm VP; Allaart CP Am J Cardiol; 2019 Aug; 124(4):560-566. PubMed ID: 31270031 [TBL] [Abstract][Full Text] [Related]
8. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy. Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245 [TBL] [Abstract][Full Text] [Related]
9. Prognostic role of NYHA class in heart failure patients undergoing primary prevention ICD therapy. Briongos-Figuero S; Estévez A; Pérez ML; Martínez-Ferrer JB; García E; Viñolas X; Arenal Á; Alzueta J; Muñoz-Aguilera R ESC Heart Fail; 2020 Feb; 7(1):279-283. PubMed ID: 31823514 [TBL] [Abstract][Full Text] [Related]
10. Long-Term Survival With Implantable Cardioverter-Defibrillator in Different Symptomatic Functional Classes of Heart Failure. Biton Y; Rosero S; Moss A; Zareba W; Kutyifa V; Baman J; Barsheshet A; McNitt S; Polonsky B; Goldenberg I Am J Cardiol; 2018 Mar; 121(5):615-620. PubMed ID: 29307459 [TBL] [Abstract][Full Text] [Related]
15. Arrhythmic burden among asymptomatic patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator. Sabbag A; Glikson M; Suleiman M; Boulos M; Goldenberg I; Beinart R; Nof E Heart Rhythm; 2019 Jun; 16(6):813-819. PubMed ID: 31153454 [TBL] [Abstract][Full Text] [Related]
16. Risk factors and the effect of cardiac resynchronization therapy on cardiac and non-cardiac mortality in MADIT-CRT. Perkiomaki JS; Ruwald AC; Kutyifa V; Ruwald MH; Mcnitt S; Polonsky B; Goldstein RE; Haigney MC; Krone RJ; Zareba W; Moss AJ; Europace; 2015 Dec; 17(12):1816-22. PubMed ID: 26071234 [TBL] [Abstract][Full Text] [Related]
17. Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. Khazanie P; Hellkamp AS; Fonarow GC; Bhatt DL; Masoudi FA; Anstrom KJ; Heidenreich PA; Yancy CW; Curtis LH; Hernandez AF; Peterson ED; Al-Khatib SM J Am Heart Assoc; 2015 Aug; 4(8):e002061. PubMed ID: 26251283 [TBL] [Abstract][Full Text] [Related]
18. Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. Fudim M; Ali-Ahmed F; Parzynski CS; Ambrosy AP; Friedman DJ; Pokorney SD; Curtis JP; Fonarow GC; Masoudi FA; Hernandez AF; Al-Khatib SM JAMA Cardiol; 2020 Jun; 5(6):643-651. PubMed ID: 32211811 [TBL] [Abstract][Full Text] [Related]
19. Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population). Zareba W; Piotrowicz K; McNitt S; Moss AJ; Am J Cardiol; 2005 Jun; 95(12):1487-91. PubMed ID: 15950580 [TBL] [Abstract][Full Text] [Related]
20. [Arrhythmia, device interventions and mortality analysis in patients with implanted cardioverter-defibrillator with/without resynchronisation therapy in dilative cardiomyopathy in primary prevention of sudden cardiac death]. Lelakowski J; Pudło J; Lelakowska-Pieła M; Rydlewska A; Piekarz J; Domaracki D Pol Merkur Lekarski; 2016 Apr; 40(238):216-22. PubMed ID: 27137820 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]